Microcap Ledger CEL SCI Corp $CVM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Vienna, VA
- Fiscal year end
- September 30
- Shares outstanding
- 17,588,987 [10-Q 2026-08-14]
What the company doesAI summary of filing
CEL-SCI Corporation is a late clinical-stage biotechnology company developing immunotherapy treatments for cancer and other diseases. The company's lead investigational product is Multikine, a Phase 3 immunotherapy being developed for treatment of certain head and neck cancers, which is administered locally before surgery. The company also develops LEAPS (Ligand Epitope Antigen Presentation System) technology with product candidates in preclinical development for rheumatoid arthritis. CEL-SCI is not revenue-generating; none of its product candidates have been approved for sale by the FDA or other regulatory agencies. [10-K 2025-12-29]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | — | −$16.60M | −$12.08M | $6.53M | [10-Q 2026-08-14] |
| FY ended Sep 2025 | — | −$25.41M | −$17.12M | $10.95M | [10-K 2025-12-29] |
| FY ended Sep 2024 | — | −$26.92M | −$18.81M | $4.74M | [10-K 2025-12-29] |
- Quarterly cash burn
- −$4.03M
- Cash runway Estimate
- ~4.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-01-06 | 74,107,041 | [10-K 2025-01-13] |
| 2025-02-10 | 77,211,541 | [10-Q 2025-02-14] |
| 2025-05-09 | 91,037,256 | [10-Q 2025-05-14] |
| 2025-08-13 | 6,882,156 | [10-Q 2025-08-14] |
| 2025-12-19 | 8,408,746 | [10-K 2025-12-29] |
| 2026-02-09 | 8,457,967 | [10-Q 2026-02-17] |
| 2026-05-11 | 8,493,111 | [10-Q 2026-05-15] |
| 2026-08-10 | 17,588,987 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-04-17; declared effective 2026-05-11 [S-1 2026-04-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Talor Eyal | grant | 1,165 | $2.06 | [4 2026-10-01] |
| 2026-09-30 | Prichep Patricia B | grant | 2,082 | $2.06 | [4 2026-10-01] |
| 2026-09-30 | Kersten Geert R | grant | 2,621 | $2.06 | [4 2026-10-01] |
| 2026-08-25 | Kersten Geert R | buy | 100,000 | $1.38 | [4 2026-08-26] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-17 | 8-K | Shareholder vote results |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-02 | DEF 14A | Proxy statement |
| 2026-06-16 | 8-K | Material agreement entered; Other events |
| 2026-06-15 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Material agreement entered |
| 2026-05-13 | 8-K | Material agreement entered; Other events |
| 2026-05-13 | 424B4 | Prospectus or prospectus supplement |
| 2026-05-01 | S-1/A | Registration statement |
| 2026-04-17 | S-1 | Registration statement |
| 2026-02-17 | 10-Q | Quarterly report |
Alerts for $CVM
Email me when CEL SCI Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.